References
- Maguire JD, Baird JK. The ‘non-falciparum’ malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies. Ann Trop Med Parasitol 2010;104:283–301.
- Bottieau E, Clerinx J, Van Den Enden E, Van Esbroeck M, Colebunders R, Van Gompel A, et al. Imported non- Plasmodium falciparum malaria: a five-year prospective study in a European referral center. Am J Trop Med Hyg 2006;75:133–8.
- Whitty CJ, Chiodini PL, Lalloo DG. Investigation and treatment of imported malaria in non-endemic countries. BMJ 2013;346:f2900.
- John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 2012;11:280.
- Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004;39:1336–45.
- Price RN, Douglas NM, Anstey NM, von Seidlein L. Plasmodium vivax treatments: what are we looking for?Curr Opin Infect Dis 2011;24:578–85.
- Schwartz E, Regev-Yochay G, Kurnik D. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 2000; 62:393–5.
- Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J 2011;10:351.
- World Health Organization. Guidelines for the treatment of malaria. Second ed. Geneva: WHO; 2010.
- Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ 1960;22:621–31.